Skip to main content

Health condition · Clinically reviewed

Invasive ductal carcinoma, the most common breast cancer, and modern UK care.

Around three-quarters of breast cancers are IDC. A modern plan combines careful surgery, radiotherapy, and systemic therapy chosen from the tumour’s molecular fingerprint.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a UK breast oncologist before publication.

  • 02

    Sourced from guidance

    Checked against NICE, ESMO, NCCN and Breast Cancer Now sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice including HER2-targeted therapy, CDK4/6 inhibitors, PARP inhibitors and immunotherapy for TNBC.

Key facts

Invasive ductal carcinoma at a glance.

The essentials, in plain English - what it is, how it presents, how it’s classified and how it’s treated in the UK today.

  • What it is

    Invasive breast carcinoma of no special type (NST) - malignant epithelial cells arising from the ductal system that have breached the basement membrane and invaded the surrounding breast stroma.

  • How common

    The most common form of breast cancer - roughly 70 to 80 percent of all invasive breast cancers diagnosed in the UK each year.

  • How it presents

    A firm breast lump, skin dimpling, nipple retraction or discharge, peau d’orange skin change, or a mass picked up on screening mammography.

  • How it’s classified

    By stage (TNM), grade (1 to 3), and molecular subtype - ER, PR, HER2 and Ki67 - which together shape every treatment decision.

  • How it’s treated

    A combination approach - surgery, radiotherapy, chemotherapy, HER2-targeted therapy, endocrine therapy and, increasingly, targeted oral drugs and immunotherapy.

  • Outlook

    Prognosis has transformed - the majority of women diagnosed with early IDC in the UK today are alive and well ten years on.

Why this guide matters

A modern plan, built around the tumour’s biology.

Breast cancer care has changed enormously in ten years. The three points below shape everything else on this page.

  • Biology drives every decision

    ER, PR, HER2 and Ki67 are checked at diagnosis - they decide whether hormone therapy, HER2-targeted drugs or chemotherapy come first.

  • Surgery is smaller and kinder

    Wide local excision with sentinel node biopsy and oncoplastic techniques deliver breast conservation and equivalent survival for most early IDC.

  • Targeted therapy has changed outcomes

    HER2-targeted antibodies, CDK4/6 inhibitors, PARP inhibitors and immunotherapy have transformed prognosis across every subtype.

How the diagnosis is made

From first symptom to a clear MDT plan.

The steps a UK breast surgeon and oncologist will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    Clinical history and family risk

    A structured review of symptoms, reproductive history and family history - including BRCA1 and BRCA2 risk, which may trigger genetic testing.

  2. 02

    Assessing

    Clinical breast examination

    A methodical examination of both breasts, axillae and supraclavicular fossae looking for a mass, skin change, nipple change or lymphadenopathy.

  3. 03

    Assessing

    Triple assessment - imaging

    Mammography and breast ultrasound as standard, with MRI in selected cases such as dense breasts, lobular features or BRCA carriers.

  4. 04

    Confirming

    Triple assessment - biopsy

    Core needle biopsy of the breast lesion and any suspicious axillary node - fine-needle aspiration is used selectively for cystic or nodal disease.

  5. 05

    Confirming

    Molecular pathology

    ER, PR, HER2 (IHC with FISH for equivocal cases) and Ki67 - the molecular fingerprint that guides systemic therapy.

  6. 06

    Confirming

    Genomic testing where indicated

    Oncotype DX or Prosigna for ER-positive, HER2-negative disease to refine chemotherapy decisions - specialist commissioned in the UK.

  7. 07

    Planning

    Staging and MDT plan

    CT chest, abdomen and pelvis plus bone scan for higher-risk disease, then a specialist breast multidisciplinary team meeting to agree the treatment plan.

Typical timeline: from breast clinic to MDT plan in around two to three weeks.

Symptoms

What invasive ductal carcinoma looks like.

A firm lump is the most common sign, but IDC can also announce itself through skin, nipple or nodal changes - and, more and more, through NHS screening.

  • Breast lump

    A firm, often painless lump - the most common presenting symptom of invasive ductal carcinoma.

  • Skin dimpling or tethering

    Localised skin dimpling caused by tumour involving the suspensory ligaments of the breast.

  • Nipple retraction or discharge

    New nipple inversion, distortion or bloody discharge - warrants prompt breast-clinic assessment.

  • Axillary lymphadenopathy

    A firm, sometimes matted node in the armpit - may be the first sign in a small proportion of women.

  • Peau d’orange skin change

    A pitted, orange-peel appearance from dermal lymphatic involvement - a red flag for locally advanced disease.

  • Paget disease of the nipple

    Eczema-like scaling of the nipple that fails to settle - can signal underlying ductal carcinoma.

  • Screen-detected mass

    A cluster of microcalcifications or a spiculated mass picked up on routine NHS breast screening mammography.

  • Red flag - inflammatory features

    Rapid-onset breast swelling, warmth and redness needs same-day two-week-wait referral - inflammatory breast cancer is rare but aggressive.

Treatment

How IDC is treated in the UK today.

Surgery, radiotherapy and systemic therapy - chosen from the tumour’s stage, grade and molecular profile at a specialist breast MDT.

  • Neoadjuvant chemotherapy

    Chemotherapy given before surgery for large, HER2-positive or triple-negative disease to shrink the tumour and improve breast-conserving surgery rates. Specialist commissioned.

  • Wide local excision plus SLNB

    Breast-conserving surgery with sentinel lymph node biopsy - the default for most early IDC, often with oncoplastic techniques for a good cosmetic result.

  • Mastectomy and reconstruction

    For multifocal, large or centrally located tumours - implant-based or autologous reconstruction is planned alongside where possible.

  • Adjuvant radiotherapy

    Standard after wide local excision, and selected after mastectomy for node-positive or high-risk disease. Hypofractionated schedules are now UK standard.

  • Adjuvant chemotherapy

    Anthracycline and taxane regimens such as FEC-T for higher-risk disease - decisions refined by genomic assays where available.

  • HER2-targeted therapy

    Trastuzumab, pertuzumab, T-DM1 (Kadcyla) and trastuzumab deruxtecan (Enhertu) - transformative for HER2-positive disease. Specialist commissioned.

  • Endocrine therapy

    Tamoxifen or an aromatase inhibitor for at least five years in ER-positive disease - the single most effective long-term therapy for hormone-driven IDC.

  • Targeted oral therapy

    CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for ER-positive disease; PARP inhibitors (olaparib, talazoparib) for BRCA-mutated disease; pembrolizumab for TNBC.

Related clinic

Trastuzumab deruxtecan clinic

Enhertu for HER2-positive and HER2-low advanced breast cancer.

Related clinic

CDK4/6 inhibitor clinic

Palbociclib, ribociclib and abemaciclib for ER-positive disease.

Related clinic

Olaparib clinic

PARP inhibitor therapy for BRCA-mutated breast cancer.

Related clinic

Immunotherapy checkpoint clinic

Pembrolizumab for triple-negative breast cancer.

Related surgery

Breast reconstruction

Implant and autologous reconstruction after mastectomy.

Related clinic

Lymphoedema compression

Long-term management after axillary surgery or radiotherapy.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and international specialist standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your breast surgeon, oncologist and clinical nurse specialist know your case in detail and can tell you which parts apply to you. If in doubt, get seen.

  • NICE. Early and locally advanced breast cancer: diagnosis and management (NG101).

  • NICE. Advanced breast cancer: diagnosis and treatment (CG81).

  • ESMO Clinical Practice Guidelines. Early breast cancer and metastatic breast cancer.

  • NCCN Guidelines. Breast Cancer, current version.

  • Royal College of Radiologists. Breast cancer radiotherapy consensus statements.

  • Breast Cancer Now and Cancer Research UK patient information resources.

Red flags

When breast symptoms need urgent attention.

Some presentations - and some situations during and after treatment - deserve same-day or same-week specialist review.

  • Inflammatory breast cancer

    Rapid-onset breast swelling, warmth, redness and peau d’orange - a two-week-wait emergency needing urgent breast-clinic assessment.

  • New nipple change

    New nipple retraction, distortion, eczema or bloody discharge in an adult - always warrants urgent breast referral.

  • Axillary or supraclavicular mass

    A new, firm node in the armpit or above the collarbone - even without a breast lump - deserves urgent imaging and biopsy.

  • Bone pain in a known survivor

    Persistent back, hip or rib pain in someone previously treated for IDC needs review - metastatic recurrence must be excluded.

  • Neurological symptoms

    New headaches, seizures, visual change or weakness in a breast cancer survivor - urgent imaging is needed to exclude brain metastases.

  • Breathlessness or persistent cough

    New respiratory symptoms in a survivor - pulmonary metastases or a pleural effusion need imaging and specialist review.

  • Severe lymphoedema flare

    A rapidly swollen, hot arm after breast surgery - may signal infection, deep-vein thrombosis or, rarely, cutaneous recurrence.

  • Contralateral breast change

    A new lump or skin change in the opposite breast during follow-up - the second breast remains at higher risk and needs prompt assessment.

  • BRCA carrier symptoms

    Any breast, ovarian or peritoneal symptom in a known BRCA1 or BRCA2 carrier needs a low threshold for specialist review.

Living with it

A survivable cancer, with strong long-term support.

Four things that make the biggest difference during and after treatment - team, movement, endocrine adherence and the wraparound support that already exists.

A quiet reminder

Recovery is a long project, not a single event.

Small, steady habits kept up for years matter more than a heroic sprint that doesn’t last.

  1. 01 Team

    Stay close to your team

    Regular breast surgeon, oncologist and clinical nurse specialist contact - phone, email or clinic - is the single best predictor of feeling in control.

  2. 02 Movement

    Move every day

    Gentle daily activity protects the arm, bones, heart and mind - and reduces the risk of recurrence in early breast cancer.

  3. 03 Endocrine

    Stick with endocrine therapy

    Five to ten years of tamoxifen or an aromatase inhibitor is hard, but it is the single most effective long-term protection against recurrence.

  4. 04 Support

    Use the support that’s there

    Breast Cancer Now, Macmillan and Maggie’s Centres offer free counselling, exercise and menopause clinics that most people underuse.

Frequently asked

Everything we get asked about IDC.

Quick answers on triple assessment, molecular subtypes, surgery choices and modern targeted drugs.

  • What is invasive ductal carcinoma?

    Invasive ductal carcinoma - now called invasive breast carcinoma of no special type - is a cancer that starts in the milk ducts of the breast and grows through the duct wall into the surrounding breast tissue. It is the most common form of breast cancer, making up around 70 to 80 percent of cases.

  • How is IDC different from ductal carcinoma in situ?

    DCIS is confined to the ducts and has not invaded surrounding tissue - it is treated as an early, non-invasive disease. IDC has broken through the duct wall and can, in theory, spread to lymph nodes or beyond. That is why staging, systemic therapy and follow-up are more involved.

  • What tests will I have when a lump is found?

    The UK standard is triple assessment in a one-stop breast clinic - clinical examination, imaging (mammography and ultrasound, sometimes MRI) and a core needle biopsy. The biopsy also tests for ER, PR and HER2, which shape treatment decisions.

  • What are ER, PR and HER2 - and why do they matter?

    They are receptors on the cancer cells that tell doctors what fuels the tumour. ER and PR positive cancers respond to endocrine therapy such as tamoxifen or an aromatase inhibitor. HER2-positive cancers respond to targeted drugs such as trastuzumab, pertuzumab and trastuzumab deruxtecan. Triple-negative cancers (ER-, PR- and HER2-negative) are treated with chemotherapy and, increasingly, immunotherapy.

  • Will I need a mastectomy?

    Not usually. Most women with early IDC can be offered wide local excision (a lumpectomy) with sentinel lymph node biopsy, followed by radiotherapy - the survival is equivalent to mastectomy. A mastectomy is offered where the tumour is large, multifocal, centrally placed, or where the woman prefers it, often with immediate breast reconstruction.

  • What new treatments have changed IDC care?

    The last decade has seen HER2-targeted drugs (trastuzumab, pertuzumab, T-DM1, trastuzumab deruxtecan and tucatinib), CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) for ER-positive disease, PARP inhibitors (olaparib, talazoparib) for BRCA-mutated disease, and pembrolizumab immunotherapy for triple-negative disease. Together they have significantly improved outcomes across every subtype.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.